Arthur Kavanaugh Selected Research

apremilast

1/2022	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
12/2021	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials.
8/2020	Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
6/2020	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
1/2020	Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
10/2019	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
1/2018	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
6/2015	Drug safety evaluation of apremilast for treating psoriatic arthritis.
3/2015	Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
6/2014	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Arthur Kavanaugh Research Topics

Disease

102	Psoriatic Arthritis 08/2022 - 04/2005
95	Rheumatoid Arthritis 01/2022 - 02/2002
40	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 04/2005
23	Arthritis (Polyarthritis) 08/2022 - 04/2005
21	Pain (Aches) 01/2020 - 02/2004
17	Infections 01/2022 - 05/2004
17	Necrosis 01/2020 - 10/2003
16	Ankylosing Spondylitis 08/2022 - 07/2006
16	Inflammation (Inflammations) 01/2022 - 07/2008
13	Fatigue 01/2021 - 02/2004
9	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 10/2005
8	Neoplasms (Cancer) 01/2022 - 07/2008
7	Rheumatic Diseases (Rheumatism) 01/2018 - 02/2006
6	Joint Diseases (Joint Disease) 01/2021 - 09/2013
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020 - 10/2002
6	Disease Progression 09/2019 - 03/2006
5	Tuberculosis (Tuberculoses) 01/2022 - 05/2004
5	Chronic Disease (Chronic Diseases) 01/2021 - 12/2015
4	Spondylitis 04/2022 - 12/2008
4	Gout 01/2017 - 03/2006
3	Opportunistic Infections (Opportunistic Infection) 01/2022 - 03/2015
3	Respiratory Tract Infections (Respiratory Tract Infection) 08/2020 - 09/2015
3	Nasopharyngitis 08/2020 - 09/2015
3	Crohn Disease (Crohn's Disease) 01/2020 - 11/2007
3	Synovitis 01/2019 - 02/2011
2	Headache (Headaches) 08/2020 - 10/2016
2	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2020 - 01/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 01/2018
2	Candidiasis (Moniliasis) 01/2020 - 01/2018
2	Hypertension (High Blood Pressure) 01/2019 - 05/2016
2	Lymphoma (Lymphomas) 11/2017 - 03/2015
2	Heart Failure 01/2016 - 01/2016

Drug/Important Bio-Agent (IBA)

43	Biological ProductsIBA 01/2022 - 09/2003
30	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 10/2002
25	Adalimumab (Humira)FDA Link 11/2020 - 07/2006
22	golimumab FDA Link 01/2022 - 04/2009
20	Tumor Necrosis Factor InhibitorsIBA 08/2022 - 05/2004
18	Antirheumatic Agents (DMARD)IBA 01/2022 - 10/2003
18	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2020 - 06/2002
17	C-Reactive ProteinIBA 08/2022 - 02/2011
13	Ustekinumab (CNTO 1275)FDA Link 01/2020 - 02/2009
12	ametantrone (HAQ)IBA 10/2020 - 02/2004
11	apremilastIBA 01/2022 - 01/2014
10	tocilizumab (atlizumab)FDA Link 05/2020 - 01/2007
10	Infliximab (Remicade)FDA Link 08/2013 - 06/2002
9	secukinumabIBA 01/2022 - 09/2015
8	tofacitinibIBA 01/2022 - 01/2014
8	Monoclonal AntibodiesIBA 01/2020 - 02/2009
7	Interleukin-17 (Interleukin 17)IBA 01/2020 - 02/2014
7	Rituximab (Mabthera)FDA Link 01/2016 - 09/2003
6	Pharmaceutical PreparationsIBA 08/2022 - 01/2003
6	Etanercept (Enbrel)FDA Link 01/2022 - 07/2006
6	LipidsIBA 01/2022 - 10/2002
6	Certolizumab Pegol FDA Link 01/2020 - 01/2009
6	Interleukin-6 (Interleukin 6)IBA 10/2016 - 01/2003
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2003
5	Interleukin-12 (IL 12)IBA 01/2020 - 02/2009
5	CytokinesIBA 09/2015 - 02/2002
5	Syk KinaseIBA 12/2014 - 11/2008
4	AntibodiesIBA 08/2022 - 03/2014
4	AntigensIBA 01/2020 - 03/2003
4	fostamatinibIBA 12/2014 - 02/2011
4	GlucocorticoidsIBA 10/2014 - 10/2003
3	GLPG0634IBA 01/2022 - 01/2018
3	Janus Kinase InhibitorsIBA 01/2022 - 12/2018
3	OxylipinsIBA 01/2022 - 01/2021
3	Rheumatoid FactorIBA 12/2021 - 05/2007
3	ixekizumabIBA 01/2021 - 07/2019
3	Prostaglandins AIBA 01/2019 - 09/2009
3	Phosphodiesterase 4 InhibitorsIBA 01/2018 - 06/2014
3	AutoantibodiesIBA 01/2018 - 02/2006
3	Uric Acid (Urate)IBA 01/2016 - 03/2006
3	InterleukinsIBA 06/2014 - 02/2009
3	Proteins (Proteins, Gene)FDA Link 01/2013 - 01/2004
3	Immunoglobulins (Immunoglobulin)IBA 10/2010 - 12/2007
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 03/2006 - 09/2003
2	bimekizumabIBA 07/2022 - 01/2020
2	HLA-B27 Antigen (HLA B27 Antigen)IBA 05/2022 - 01/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 06/2011
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 03/2021
2	Anti-Citrullinated Protein AntibodiesIBA 12/2021 - 01/2008
2	cyclic citrullinated peptideIBA 12/2021 - 01/2008
2	Leflunomide (Arava)FDA LinkGeneric 06/2020 - 08/2004
2	Antiphospholipid AntibodiesIBA 01/2020 - 01/2020
2	Interleukin-23 (Interleukin 23)IBA 12/2019 - 06/2014
2	amsonic acid (DAS)IBA 05/2019 - 01/2019
2	Biosimilar PharmaceuticalsIBA 01/2019 - 01/2018
2	GP2015IBA 01/2019 - 01/2018
2	SteroidsIBA 01/2018 - 02/2011
2	EpitopesIBA 01/2018 - 11/2009
2	Pegloticase FDA Link 01/2017 - 03/2014
2	Lipoproteins (Lipoprotein)IBA 10/2016 - 10/2002
2	VaccinesIBA 01/2016 - 01/2016

Therapy/Procedure

69	Therapeutics 04/2022 - 02/2002
8	Biological Therapy 01/2018 - 07/2007
3	Subcutaneous Injections 01/2020 - 04/2009
2	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2020 - 01/2020
2	Contraception (Birth Control) 01/2020 - 01/2020
2	Excimer Lasers 09/2019 - 01/2012
2	Aftercare (After-Treatment) 11/2018 - 10/2016